Jubilant Biosys Limited Announces New Chemistry Innovation ResearchCenter to Support Expanded Discovery Chemistry and in-vitro ADME
Services for Clients like Turning Point Therapeutics.
November 11, 2021 – San Diego, CA, USA & Bengaluru, India — Jubilant Biosys Limited
announced today, an expansion of its facilities to support its discovery chemistry and in-vitro
ADME Service offerings. Jubilant Biosys provides services for Turning Point Therapeutics
Inc. for multiple small molecule oncology research programs. Turning Point is a precisiononcology company developing next-generation therapies that target genetic drivers ofcancer.
Services for Turning Point Therapeutics Inc. will be conducted out of Jubilant Biosys Limited’s
newly built state-of-the-art Chemistry Innovation Research Center (CIRC) in Greater Noida,
India. It’s Chemistry Innovation Research Center has an initial capacity of 500 FTEs enablinghigher operational performance for discovery chemistry services and also rapid turn-aroundof in-vitro ADME data for client projects.
Commenting on this expansion, Giuliano Perfetti, Chief Executive Officer, Jubilant Biosys
Limited said, “We are delighted to unveil our newly built Chemistry Innovation ResearchCenter, Greater Noida for Turning Point’s and our other clients’ project needs and we arelooking forward to accelerating their programs through this site.”“We are excited to continue our relationship with Jubilant Biosys Limited as they start using
their CIRC. They continue to provide skilled contract services for challenging synthetic
chemistry projects while realizing the importance of short cycle times to deliver and provide
critical in-vitro ADME data for our growing portfolio.” said Siegfried Reich, Ph.D., chief
scientific officer, Turning Point Therapeutics.
About Jubilant Biosys LimitedJubilant Biosys Limited, a subsidiary of Jubilant Pharmova Limited, an integrated global
pharmaceutical company, has presence in Bengaluru and Noida in India. Jubilant Biosys
offers contract research & development services for global pharmaceutical innovators.
Jubilant Biosys has demonstrated expertise in functional services in chemistry includingcomputational, medicinal/ synthetic chemistry, PR&D and GMP scale-up capabilities up tophase II. Services in biology include structural biology, in-vitro biology, DMPK, in-vivo
pharmacology and Toxicology. Further, Jubilant Biosys has integrated discovery expertisewith a track record of working on over 80 programs in multiple therapeutic areas including
but not limited to Oncology, Metabolic Disorders, Pain & Inflammation, CNS and expanding
into Rare Diseases.
For more info: www.jubilantbiosys.com
Business Development Contact:
Ravichandran S
bd@jubilantbiosys.com

About Turning Point Therapeutics
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline ofinternally discovered investigational drugs designed to address key limitations of existing
cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation
kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer
and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2
study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity anddurable responses among kinase inhibitor treatment-naïve and pre-treated patients. The
company’s pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R andSRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solidtumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being
studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring
genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being
studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced ormetastatic non-small cell lung cancer. The company is driven to develop therapies that marka turning point for patients in their cancer treatment. For more information, visit
www.tptherapeutics.com.
Media Contact:
Scott Lipman
ir@tptherapeutics.com
858-876-3985
About Jubilant Pharmova Limited
Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engagedin Pharmaceuticals, Contract Research and Development Services and Proprietary Novel
Drugs businesses. Pharmaceuticals business through Jubilant Pharma Limited Singapore(JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of 48
radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile
Injectables and Non-sterile products, APIs and Solid Dosage Formulations through six
manufacturing facilities that cater to all the regulated market including USA, Europe and othergeographies. Jubilant Biosys Limited provides contract research and development services
through two world class research centers in Bangalore and Noida in India. Jubilant Pharmova
Limited has a team of over 6,000 multicultural people across the globe. The Company is wellrecognized as a ‘Partner of Choice’ by leading pharmaceuticals companies globally. For more
information, please visit: www.jubilantpharmova.com
Available on